CytoSorbents to host KOL, Analyst-Investor Day

CytoSorbents Corporation announced that it will host a virtual Key Opinion Leader, KOL, and Analyst-Investor Day on Monday, May 6, 2024. The program will cover the significant challenge of severe perioperative bleeding in patients undergoing heart surgery while on blood thinners, including the drug Brilinta. Notably, the experts will review the key findings from the pivotal U.S. and Canadian STAR-T randomized, controlled trial, investigating the safety and efficacy of DrugSorb-ATR to mitigate this issue and the exciting data in the pre-specified CABG population. In addition, the program will include an overview of real-world use and outcomes with antithrombotic drug removal in cardiac surgery in the European Union, where the application is already approved.